Studies demonstrate protection against gastric ulcers, intestinal damage, and inflammatory bowel conditions
Appears to enhance weightloss and glucose effects when combined with GLP1, based on dualagonist data (such as tirzepatide). Glucagon receptor activation Increases energy expenditure and promotes fat oxidation when balanced properly with GLP1 and GIP. May help reduce liver fat and visceral (deep abdominal) fat, which are strongly linked to cardiometabolic risk. By combining these three pathways, retatrutide aims to reduce appetite, improve metabolic control, and increase calorie burning more strongly than current single or dualagonist drugs
Hormonal modulators : buoyed by the success of therapeutically exploiting incretins, biotechs/pharma are exploring whether agonism of other GI hormones can similarly induce weight loss
The ATTAIN Phase 3 global clinical development program for orforglipron has enrolled more than 4,500 people with obesity or overweight across two global registrational trials
In vitro studies on aged human lymphocytes found that Epitalon reversed this heterochromatinization, increasing chromatin plasticity and making DNA more accessible to transcription factors
maybe they no longer feel the social pressure to drink